Liver cancer
Conditions
Interventions
Experimental group:D-TACE+PD-1 inhibitors + antiangiogenic drugs
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients with HCC who strictly meet the clinical diagnostic criteria of The Code for The Diagnosis and Treatment of Primary Liver Cancer (2019 edition) or who have been confirmed by histopathological or cytological examination are unable to undergo surgical treatment or unwilling to undergo surgical treatment; 2.Complete preoperative laboratory examination and liver enhanced CT and/or MRI image data; 3.STAGE C of BCLC or Stage B unsuitable for radical surgery; 4.Child-Pugh liver function rating: GRADE A or better grade B (= 18 years, male or female; 6.ECOG PS score: 0-2; 7.The main organs function normally, that is, they meet the following criteria: (1)Blood routine examination :(no blood transfusion, no G-CSF, no drug correction within 14 days before screening) HB >= 90 G/L;The ANC acuity 1.5x10^9/L;PLT 50x10^9/L or higher; (2)Biochemical examination:(no ALB infusion within 14 days) ALB >= 30g/L, ALT and AST < 5 ULN; TBIL < =2 ULN; Creatinine <= 1.5 ULN; 8.Subjects voluntarily joined the study and signed informed consent with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1.Hepatobiliary duct cell carcinoma and mixed cell carcinoma; 2.Patients who have received systematic treatment in the past; 3.CT or MRI imaging suggested the existence of obvious arteriovenous fistula; 4.Recent (<= 3 months) gastrointestinal bleeding (hematemesis or melena); 5.With severe infection such as liver abscess; 6.Patients with other uneffectively controlled malignant tumors; 7.Patients combined with HIV infection; 8.The investigator determines other conditions that may affect the conduct of the clinical study and the determination of the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Disease control rate;Objective remission rate; | — |
Countries
China
Contacts
Public ContactZeng Hui
Zhejiang Cancer Hospital
Outcome results
None listed